| 0.85 -0.03 (-3.37%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.03 | 1-year : | 1.21 |
| Resists | First : | 0.88 | Second : | 1.03 |
| Pivot price | 0.75  |
|||
| Supports | First : | 0.65 | Second : | 0.5 |
| MAs | MA(5) : | 0.83 |
MA(20) : | 0.7 |
| MA(100) : | 0.77 |
MA(250) : | 1.22 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 88.4 |
D(3) : | 84.6 |
| RSI | RSI(14): 66.3 |
|||
| 52-week | High : | 2.52 | Low : | 0.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BLRX ] has closed below upper band by 26.6%. Bollinger Bands are 34.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.89 - 0.9 | 0.9 - 0.9 |
| Low: | 0.8 - 0.81 | 0.81 - 0.81 |
| Close: | 0.84 - 0.85 | 0.85 - 0.86 |
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Fri, 26 Jul 2024
BioLineRx Ltd. (NASDAQ:BLRX) Short Interest Down 63.1% in July - Defense World
Thu, 25 Jul 2024
BioLineRx Ltd. (NASDAQ:BLRX) Sees Significant Decrease in Short Interest - MarketBeat
Mon, 15 Jul 2024
Short Interest in BioLineRx Ltd. (NASDAQ:BLRX) Expands By 52.9% - Defense World
Tue, 28 May 2024
BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript - Seeking Alpha
Tue, 02 Apr 2024
Does BioLineRx (TLV:BLRX) Have A Healthy Balance Sheet? - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 80 (M) |
| Shares Float | 990 (M) |
| Held by Insiders | 8.5 (%) |
| Held by Institutions | 1.7 (%) |
| Shares Short | 212 (K) |
| Shares Short P.Month | 356 (K) |
| EPS | -0.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -70.4 % |
| Return on Assets (ttm) | -40.5 % |
| Return on Equity (ttm) | -188.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.14 |
| EBITDA (p.s.) | -0.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -29 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -1.12 |
| PEG Ratio | 0 |
| Price to Book value | 85 |
| Price to Sales | 5.83 |
| Price to Cash Flow | -2.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|